Bedrijfsoverzicht
Centessa Pharmaceuticals plc is a specialized biotechnology entity focused on the discovery, development, and delivery of orexin-based neuroscience therapeutics within the markets of the United Kingdom and the United States. The company operates within the broader Healthcare sector, specifically functioning in the Biotechnology industry, a classification that denotes its involvement in the creation of novel biological treatments rather than traditional small-molecule drugs. With a current market capitalization of $6.11 billion, the firm employs 118 individuals to advance its pipeline, most notably ORX750, an orexin receptor 2 agonist currently undergoing Phase IIa clinical trials for the treatment of central nervous system disorders. The reported revenue of $15.00 million over the trailing twelve months combined with a market cap of $6.11 billion indicates a significant valuation premium relative to its current sales base, a common characteristic for biotechnology firms where future potential from approved therapies drives value rather than immediate cash flow generation.
Financiële gezondheid
Over the trailing twelve-month period, Centessa reported revenues of $15.00 million, yet this activity resulted in a net income loss of $197,532,000, revealing a cost structure where expenses significantly outpace revenue generation. The company's EBITDA stands at $-207,371,008, further illustrating the high burn rate typical of clinical-stage development where research and development expenditures are substantial. Free cash flow for the period was recorded at $-138,539,376, indicating that the company is consuming cash to fund operations and development, which limits immediate financial flexibility but is necessary for progressing clinical assets. The gross margin is reported at 100.0%, reflecting the accounting treatment of cost of goods sold in the biotechnology sector prior to the heavy inclusion of R&D expenses in operating costs. In contrast, the operating margin is -1384.6% and the profit margin is 0.0%, highlighting that operating expenses and other costs far exceed the gross revenue contribution, resulting in a negative bottom line. The balance sheet shows a cash position of $294.58M against total debt of $118.38M, resulting in a debt-to-equity ratio of 22.47, suggesting a capital structure heavily reliant on equity financing rather than debt obligations. Despite the high debt-to-equity figure, the current ratio of 8.57 indicates robust short-term liquidity, as current assets are nearly nine times greater than current liabilities. Return on Equity is -42.6% and Return on Assets is -20.5%, metrics that demonstrate management is currently deploying capital to generate losses rather than positive returns, a standard phase for companies in deep clinical development.
Waarderingsbeoordeling
The trailing twelve-month P/E ratio is listed as N/A due to the negative net income, while the forward P/E is calculated at -20.82, implying that the market is pricing in future earnings potential rather than current profitability. The price-to-book ratio stands at 11.18, indicating that the market values the company at more than eleven times its book value, a significant premium that reflects the intangible value of the clinical pipeline and intellectual property. Alternative valuation metrics such as the price-to-sales ratio of 407.07 and the EV/EBITDA of -28.58 suggest that investors are valuing Centessa primarily on the potential future sales of its drug candidates rather than existing financial performance. The stock has traded between a 52-week low of $10.95 and a 52-week high of $40.26, and without a specific current price in the provided data, the valuation is contextualized by this wide trading range which underscores the volatility of biotechnology equities. The beta of 1.26 indicates that the stock's price volatility is 26% higher than the broader market, meaning the asset experiences greater price swings during periods of market turbulence compared to large-cap equities.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, preventing a direct comparison of growth rates between sales and profitability within the available data. Consequently, it is impossible to determine from the provided figures whether earnings are growing faster or slower than revenue, as historical growth trajectories are not quantified in the dataset. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning all available cash flow is retained and reinvested into research, development, and clinical trials rather than distributed to shareholders. This reinvestment strategy is typical for biotechnology firms at the clinical trial stage, where capital preservation and pipeline advancement take precedence over income generation. The overall growth and income profile is characterized by a lack of current profitability and dividend income, relying entirely on external capital markets and internal cash reserves to sustain operations and fund the development of ORX750.